These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26243074)

  • 1. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity.
    Beierlein JM; McNamee LM; Walsh MJ; Ledley FD
    Clin Ther; 2015 Aug; 37(8):1643-51.e3. PubMed ID: 26243074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling timelines for translational science in cancer; the impact of technological maturation.
    McNamee LM; Ledley FD
    PLoS One; 2017; 12(3):e0174538. PubMed ID: 28346525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities.
    Beierlein JM; McNamee LM; Walsh MJ; Kaitin KI; DiMasi JA; Ledley FD
    Clin Ther; 2017 Jul; 39(7):1409-1425.e20. PubMed ID: 28652015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.
    Salminen A; Kaarniranta K; Kauppinen A; Ojala J; Haapasalo A; Soininen H; Hiltunen M
    Prog Neurobiol; 2013; 106-107():33-54. PubMed ID: 23827971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies.
    Ledley FD; McNamee LM; Uzdil V; Morgan IW
    Gene Ther; 2014 Feb; 21(2):188-94. PubMed ID: 24305420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. As Technologies for Nucleotide Therapeutics Mature, Products Emerge.
    Beierlein JM; McNamee LM; Ledley FD
    Mol Ther Nucleic Acids; 2017 Dec; 9():379-386. PubMed ID: 29246316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
    Kumar S; Chowdhury S; Kumar S
    BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond.
    Ganjei JK
    Drug News Perspect; 2010 Nov; 23(9):573-84. PubMed ID: 21152452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in Alzheimer's disease drug discovery: an update.
    Williams M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease.
    Huse JT; Doms RW
    Mol Neurobiol; 2000; 22(1-3):81-98. PubMed ID: 11414282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?
    Mullane K; Williams M
    Biochem Pharmacol; 2013 Feb; 85(3):289-305. PubMed ID: 23178653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease drug development based on Computer-Aided Drug Design.
    Zeng H; Wu X
    Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.